The drug ACETEC contains one active pharmaceutical ingredient (API):
Enalapril is a derivative of two amino-acids, L-alanine and L-proline. After absorption, enalapril is hydrolysed to enalaprilat, which inhibits ACE. Inhibition of ACE results in decreased plasma angiotensin II, which leads to increased plasma renin activity (due to removal of negative feedback of renin release), and decreased aldosterone secretion.
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
This brand name is authorized in the following countries: Australia New Zealand
This drug has been assigned below unique identifiers within the countries it is being marketed: